Clinical Research Services

The combination of the MHRA Accreditation and the expert knowledge of conducting 500 Early Phase Studies ensure Richmond Pharmacology can provide you with a service that meets your needs.

Adaptive Phase I Studies

Rapid approval, flexible conduct, adaptive protocols in a MHRA accredited facility.

View service

TQT Studies

World-class specialist clinic and core laboratory all under one roof.

View service

Bridiging Studies

International specialist provider of Japanese Bridging Studies since 2002.

View service

Patient Recruitment

Fast and efficient in-house team, specialising in patient recruitment

View service

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more